1	Elevated mucosal antibody responses against SARS-CoV-2 are
2	correlated with lower viral load and faster decrease in systemic COVID-19 symptoms
3	
4	Janeri Fröberg <sup>1,2*</sup> , Joshua Gillard <sup>1,2,3*</sup> , Ria Philipsen <sup>1,2,4</sup> , Kjerstin Lanke <sup>2</sup> , Joyce Rust <sup>1,2,4</sup> ,
5	Diana van Tuijl <sup>1,2,4</sup> , Teun Bousema <sup>2</sup> , Elles Simonetti <sup>1,2</sup> , Christa E. van der Gaast – de Jongh <sup>1,2</sup> ,
6	Mariska Bos <sup>1,2</sup> , Frank J. van Kuppeveld <sup>5</sup> , Berend-Jan Bosch <sup>5</sup> ,
7	Marrigje Nabuurs- Franssen <sup>6</sup> , Nannet van der Geest-Blankert <sup>7</sup> , Charlotte van Daal <sup>7</sup> ,
8	Martijn A. Huynen <sup>3</sup> , Marien I. de Jonge <sup>1,2#</sup> , Dimitri A. Diavatopoulos <sup>1,2#</sup>
0	

#### 9

#### 10 **Affiliations:**

<sup>1</sup>Radboud university medical center, Radboud Institute for Molecular Life Sciences, Laboratory of 11 Medical Immunology, Section Paediatric Infectious Diseases, Nijmegen, 6525 GA Nijmegen, The 12 13 Netherlands, <sup>2</sup>Radboud Center for Infectious Diseases, Radboudumc, Nijmegen, <sup>3</sup>Centre for molecular 14 and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre Nijmegen, 6525 GA Nijmegen, The Netherlands, <sup>4</sup> RTC CS Radboud Technology 15 16 Center Clinical Studies, Radboudumc, Nijmegen, <sup>5</sup>Utrecht University, Faculty of Veterinary 17 Medicine, Department of Biomolecular Health Sciences, Division Infectious Diseases and 18 Immunology, Utrecht, the Netherlands <sup>6</sup>Department of medical microbiology and infectious diseases, 19 Canisius Wilhelmina hospital, Nijmegen, <sup>7</sup>Department of Occupational Health, Radboud university medical centre 20 21

22 Correspondence to: Dr. Dimitri A. Diavatopoulos, Radboud university medical center, Radboud 23 Institute for Molecular Life Sciences, Department of Laboratory Medicine, Nijmegen, 6525 GA

24 Nijmegen, The Netherlands. Email correspondence to: dimitri.diavatopoulos@radboudumc.nl

25 \*, # contributed equally

#### 26 ABSTRACT

- 27 Mucosal antibodies play a key role in protection against SARS-CoV-2 exposure, but their role during
- 28 primary infection is not well understood. We assessed mucosal antibody responses during primary
- 29 infection with SARS-CoV-2 and examined their relationship with viral load and clinical symptoms.
- 30 Elevated mucosal IgM was associated with lower viral load. RBD and viral spike protein-specific
- 31 mucosal antibodies were correlated with decreases in systemic symptoms, while older age was
- 32 associated with an increase in respiratory symptoms. Up to 42% of household contacts developed
- 33 SARS-CoV-2-specific mucosal antibodies, including children, indicating high transmission rates
- 34 within households in which children might play an important role.

Transmission within households is an important contributor to the spread of SARS-CoV-2, as close

#### **35 INTRODUCTION**

- 37 contact within households facilitates early-onset pre-symptomatic transmission of the virus.<sup>1-3</sup> The rapid spread of SARS-CoV-2 in populations is attributed to several aspects of the virus, i.e. route of 38 transmission via respiratory droplets, rapid viral replication and shedding from the upper-respiratory 39 tract<sup>4</sup>, early infectiousness with a peak viral load before onset of symptoms<sup>5,6</sup>, and a high frequency of 40 mild and asymptomatic infections<sup>6-10</sup>. These aspects make controlling the outbreak difficult, as current 41 control strategies are primarily dependent on symptomatic case detection<sup>11,12</sup>. Additionally, they 42 indicate a high probability that pre-symptomatic carriers are important drivers of community-based 43 transmission of the virus<sup>11,13</sup>. The role of children in transmission remains a highly debated subject, as 44 children often develop asymptomatic or atypical disease which makes them prone to 45 underdiagnosis<sup>3,9,14</sup>. A better understanding of the virology, immunology and clinical symptoms of 46
- 47 mild SARS-CoV-2 infections in a community setting is therefore essential to track the spread of
- 48 SARS-CoV-2 in the general population, and to inform intervention measures.
- 49

36

50 Antibodies play a crucial role in the protection against viral re-infection by neutralizing the virus upon

- 51 re-entry. SARS-CoV-2 enters human cells by binding to the ACE2 receptor with the receptor binding
- 52 domain (RBD) of the Spike (S) protein. Serological studies have shown that antibodies directed
- against these antigens are capable of hindering SARS-CoV-2 infection, and vaccines targeting the S
- 54 protein have been shown to be efficacious  $^{4,6,15,16}$ . Infection with SARS-CoV-2 also induces humoral
- responses against the highly immunogenic nucleocapsid (N) protein. The N protein of SARS-CoV-2
- shares approximately 80% of its amino acid sequence with SARS-CoV-1 and other seasonal
- 57 coronaviruses<sup>17</sup>. Therefore, pre-existing immunity against the N-protein may play a protective role
- 58 during infection<sup>17,18</sup>. Studies investigating antibody response dynamics in mild cases have
- demonstrated the development of serum antibodies against SARS-CoV-2 approximately 10-15 days
- 60 post symptom onset<sup>4,19</sup>. Relevance of serum antibodies to protection of severe disease is however
- equivocal, as some studies found that the antibody response in mild infections is transient $^{20,21}$ , while
- 62 others reported robust and long-lasting antibody responses following mild infections<sup>22,23</sup>.
- 63

64 An understudied aspect of the immune response to SARS-CoV-2 infection is the magnitude and 65 kinetics of the mucosal antibody response. Studies of other coronaviruses conducted with controlled 66 laboratory exposure have shown that mucosal antibodies play a key role in the reduction of viral load 67 and may contribute to protection following re-exposure<sup>24,25</sup>. However, the vast majority of antibody studies on SARS-CoV-2 in humans thus far have focused on serum measurements, with relatively 68 little attention to mucosal antibodies. To obtain a comprehensive view on the role of mucosal immune 69 70 responses in mild SARS-CoV-2 infection, we performed a prospective, observational household 71 contact study. We assessed the timing, magnitude and complexity of mucosal antibody responses

- against SARS-CoV-2 antigens and examined their associations with viral load and COVID-19 related
- raging symptom development. Additionally, serological and mucosal antibody measurements were used to
- identify additional cases among close household contacts that were tested negative by PCR at study
- start. We observed the strongest increases in mucosal antibodies for IgM and IgG directed against S
- and RBD early after symptom onset, with elevated mucosal IgM levels associated with lower viral
- 77 load. Increased RBD and S-specific mucosal antibodies correlated with decreases in systemic
- symptoms over the study period, while older age was associated with an increase in respiratory
- symptoms. Finally, we demonstrate that up to 42% of participating household contacts develop
- 80 antibodies to SARS-CoV-2, including children, suggesting high transmission among household
- 81 contacts. Child contacts were infected at a similar rate as adult contacts with similar viral load, but
- 82 developed less symptoms compared to adults. Therefore the role of children in transmission might be
- 83 underestimated.
- 84

### 85 **RESULTS**

#### 86 <u>Cohort description and study design</u>

87 The recruitment strategy for inclusion of households focused on healthcare workers with a PCR-

88 confirmed infection who were in home isolation (index cases) with at least two participating

household members. Between 26 March 2020 and 15 April 2020, we enrolled 50 index cases and 137

90 household members (Figures 1a and b). Home visits were planned to collect naso and oropharyngeal

swab samples and nasal mucosal lining fluids (MLF) on the day of study enrolment (D0). In addition,

92 MLFs were self-sampled on three subsequent timepoints and a serum sample was collected on the last

day of the study. Index cases were asked to report their first day of symptoms, and all volunteers were

asked to complete a daily symptom survey in order to monitor disease progression (Figure 1c). The

analysis of mucosal antibody responses was compared with viral load, serological and symptom data.

96 The general characteristics of study participants are shown in <u>**Table S1**</u>. Index cases were mostly

97 female (76%) which is reflective of the gender amongst healthcare workers, with a median age of 46

98 (IQR: 37-54), while household members were mostly male (61%) and younger, with a median age of

21 (IQR:13-46). At inclusion, 46 (92%) of the index cases and 48 (35%) of the household members

100 were PCR positive.

101

#### 102 <u>Serum antibody responses against SARS-CoV-2 in index cases and their household members</u>

103 The magnitude of antibody responses was measured in serum and MLF using a fluorescent-bead-

based multiplex immunoassay to quantify IgG, IgA and IgM isotypes specific for S- N- and RBD-

antigens. We divided the log2-transformed antibody levels by the mean of control samples collected in

the pre-SARS-CoV-2 period (n=32 for serum, and n=17 for MLF), to create a normalized value

107 (relative ratio) that reflects the signal over background measurements.

108 Serum antibody responses, measured at the end of the study, were significantly higher in index cases

109 than in controls for all antigens and isotypes (Figure S1). In order to evaluate differences between

antibody isotype and antigen specificities, index cases were classified as seroconverted for each

antigen and isotype, based on the difference between their sample and the negative control samples.

By the end of the study, 96% of index cases and 53.28% of household members (contacts)

seroconverted based on at least one antibody measurement, and the highest seroconversion rate was

114 found for the S-protein (Figure 2a). Nearly all index cases (96%) seroconverted for S-protein IgG and

115 IgA, while the seroconversion rate for RBD and N-protein was substantially lower or even absent (50

and 70% for IgG and 2 and 0% for IgA, respectively). Similar patterns were found in the household

117 contacts. In order to compare local (respiratory) versus systemic humoral immune responses, we

118 correlated serum and MLF measurements taken at the end of the study. All correlations were positive

and statistically significant, and were strongest for the IgM and IgG isotypes (Figure 2b), as has been

120 previously reported for saliva and serum immunoglobulins  $^{26-28}$ .

#### 122 Mucosal antibody responses against SARS-CoV-2 in index cases

123 To examine the relationship between mucosal antibodies and virologic and clinical features, we 124 focused on the index cases (n=50), as this group reported a date of symptom start. All index cases 125 were included within two weeks of first experiencing symptoms (Figure S2a), and all data of the index cases were collected between 0 and 40 days post symptom onset (PSO) (Figure S2b), making 126 127 the index cases a suitable cohort to examine these relationships during the acute phase of COVID-19 128 disease. The viral load at study enrolment was non-significantly lower when the individual had a 129 longer period of symptoms before study start (Figure s3). We correlated MLF antibody measurements 130 collected at study start with viral load and the days since symptom onset. A higher mucosal IgA 131 antibody level at enrolment was correlated with a longer period of symptoms before study start, while 132 viral load was negatively correlated with IgM levels specific for RBD and S antigens (Figure 3a). This correlation pattern persisted after adjusting for age, sex, days since symptom onset for the viral 133 load correlation, and viral load for the days since symptom onset correlation (data not shown). 134 135 136 To examine the kinetics of the mucosal antibody response, we measured the magnitude of antibody responses in the mucosal lining fluid of index cases at study day 0, 3, 6, and 28. Previous studies have 137 shown that coronavirus-specific antibodies are significantly elevated in serum around two weeks PSO 138 <sup>26,27,29</sup>. We examined longitudinal mucosal antibody responses by binning samples into three-day 139

140 timeframes relative to the day of symptom onset and plotting the values alongside controls. Mucosal

timeframes relative to the day of symptom onset and plotting the values alongside controls. Mucosal
 IgM, IgA, and IgG antibody levels for S and RBD antigens were significantly elevated relative to

142 controls between 7-9 days PSO and remained high up to 40 days PSO, while for N protein only IgG

143 antibody responses were significantly higher than controls after 28 days PSO (Figure 3b).

144 In order to study the temporal changes in the relationship between the antibody-antigen types, we

145 calculated correlations among antibody responses within each timeframe. While IgA, IgG and IgM

isotypes were highly intercorrelated between S and RBD near the start of symptom onset, at the final

147 measurement (28+ days POS) correlations between the IgA-S and IgA-RBD isotype were much

148 weaker. Correlations of N-protein antibodies with S and RBD were overall weaker until at least two

149 weeks PSO, at which point the IgG-N response correlated with the IgG-RBD and IgG-S antibody

150 measurements (Figure 3c).

151 Thus, SARS-CoV-2 infection induces a robust IgA, IgG, and IgM mucosal antibody response

primarily against the S and RBD antigens as early as 7-9 days post symptom onset, while antibodies

against N-protein show a different, slower induction and are overall restricted to IgG.

154

# 156 Symptom progression in COVID-19 patients

Mild COVID-19 disease is highly variable in its presentation and is generally characterized as a 157 SARS-CoV-2 infection that does not require hospitalization or oxygen support and is not accompanied 158 by severe symptoms like pneumonia<sup>4,8,30</sup>. We examined the progression of 23 symptoms using a 159 survey that all volunteers filled in daily throughout the follow-up. To analyse the clinical 160 161 manifestation of mild COVID-19 disease over a period soon after symptom onset, we focused on the 162 index cases. The most frequently reported symptoms across the entire study period were fatigue, rhinorrhea, coughing, headache, and anosmia (Figure S4a). In order to compare different aspects of 163 164 the clinical presentation, we grouped the symptoms into three categories: gastrointestinal symptoms 165 (GS), systemic disease symptoms (SDS) and respiratory symptoms (RS). All index cases reported 166 symptoms at the start of the study (Figure S4b). Fatigue was reported very frequently, and as such was not categorized (Figure S4a and b). We examined whether the symptom duration varied between 167 168 different clinical presentations, and calculated the duration for each index case for each symptom group. The duration of SDS was significantly shorter than RS, and by the end of the study period 169 170 nearly all index cases had resolved their SDS, while a quarter still reported RS (Figure S4c). To examine longitudinal changes in the magnitude of COVID-19 symptoms, we binned symptom 171 172 notifications into three-day timeframes relative to the day of symptom onset, similar to the antibody analysis. While the number of SDS rapidly decreased from the time of symptom onset, RS appeared to 173 stay high for at least two weeks post symptom onset (Figure 4a). We investigated if patient 174 characteristics were associated with changes in symptoms over time. We constructed a linear mixed-175 176 effects model per symptom group with the number of reported symptoms as the response and time 177 since symptom onset, age, and sex as covariates. Such a linear model was a good fit for our longitudinal symptom data (Figure S5). While time was significantly associated with decreases in 178 179 symptoms, age was significantly associated with increased RS when correcting for the effect of time 180 (p-value = 0.0165, Figure 4b). The sex had no effect on any symptom response group. To ascertain 181 whether the induction of mucosal antibodies was associated with COVID-19 symptoms, the 182 longitudinal mucosal antibody measures were added to the model in a univariate manner. This way, 183 estimated changes in symptoms per unit increase of antibody signal represent the additional effect of antibodies while controlling for time, age, and sex. Increases in mucosal antibodies overall were 184 185 associated with decreased SDS and RS. A significant association was only found for SDS, where high 186 levels of IgM and IgG for S and all isotypes for RBD were related to a decrease in symptoms. The largest effect was seen in the relation between IgA-RBD and SDS (Figure 4c). 187 188

....

#### 190 SARS-CoV-2 infections in household contacts

To examine infections amongst household clusters, we classified household contacts into cases or non-191 192 cases. Cases were classified first by their PCR result on enrolment, followed by seroconversion for 193 one of the antibody isotypes against S-protein and mucosal antibody responses against S-protein at the 194 end of the follow-up. The PCR positive threshold was set at a Ct value <36, corresponding to a viral 195 load of  $\geq 10^3$  copies/ml. The seroconversion threshold was based on the mean + 2\*SD of the log2-196 transformed pre-SARS-CoV-2 control samples. To identify cases based on mucosal antibodies against 197 S, we used a naive Bayes model that was trained by the mucosal antibody measurements of the PCR 198 positive study participants (cases) and the pre-SARS-CoV-2 control samples (controls). Together, this 199 approach identified 75 cases amongst 137 (54.7%) household contacts (Figure 5a), of whom 64% 200 were PCR positive at study start, 87% were seropositive at the end of the follow-up, and 76% were identified as a case based on the MLF antibody levels at the end of follow-up (table S2). The majority 201 202 of PCR positive cases also developed serum and MLF antibodies at the end of the study (88%). By 203 including antibody measurements, 27 additional cases were identified (36% of cases). 204 All participants were asked if they were the first with COVID-19 related symptoms (primary case) in 205 206 the household (parents were asked to answer for young children). This classification was solely based 207 on symptoms, as only healthcare workers were eligible for PCR testing at the time of this study. Among the contacts included in the study, nine were reported to be the primary case based on the 208 209 timing of symptom onset. When we correlated their mucosal antibody responses to viral load, a similar 210 negative correlation of IgM levels with viral load was observed for the S and RBD antigens as in the 211 index cases (Figure 5b). We hypothesized that the primary cases within the household contacts would 212 have been symptomatic for a longer period than the non-primary contacts. To see if this different stage 213 of infection would be reflected in a difference in mucosal antibody levels, we plotted their mucosal

- antibody values in a similar manner as the index cases, using the day of symptom onset of the index
- case in the respective household as we did not have this data for the contacts. We found that primary
- cases, compared to secondary cases, had earlier and overall higher antibody responses for all antibody
- 217 isotypes of S and RBD antigens (**Figure 5b**). Similar to the index cases, IgM and IgA antibody
- responses against the N-protein were relatively weak and were in range of the pre-SARS-CoV-2
- control samples.
- 220 The role of children in transmission of SARS-CoV-2 has been the subject of significant discussion.
- 221 We therefore examined the likelihood that children <12y become infected. We found that 16 of the 33
- 222 (48.5%) of the children <12y were infected, which was not significantly different compared to the
- 59/104 (53.8%) in the >12y household contacts (p-value:0.78, Figure 6a). In the contacts above 50
- years, the proportion of infection was the highest (19/31, 61%). Most of these infected contacts above
- 50 years were the partner of the index case (12/19, 63%), while all infected participants <12y were

- children of the index case. Of note, 29% of all infected household members did not have any
- symptoms at study start, and 19% of all infeceted contacts remained asymptomatic throughout the
- entire follow-up. When examining the distribution of asymptomatic cases among the four age groups,
- we found that 7 out of the 16 (44%) cases <12y were asymptomatic at study start, compared to 11 of
- the 59 (20%) cases above 12y (p-value:0.10, Figure 6b). When we examined the overall number of
- symptoms that was reported throughout the follow-up, we noticed a strong and significant positive
- correlation between number of symptoms and age (Figure 6c). Despite the lower number of
- symptoms or absence of symptoms in child cases, no differences were found in viral load compared to
- the older age categories, nor were the serum antibody levels at the end of the follow-up different
- between the age-groups (Figure s6a and b).
- 236
- 237
- 238

#### 239 DISCUSSION

240 In this study, we examined the mucosal antibody responses following infection with SARS-CoV-2 and

- the development of mild COVID-19 disease in 50 adults and their household contacts. This study
- demonstrates the unique value of using mucosal lining fluid to assess various aspects of SARS-CoV-2
- infection, ranging from pathophysiology to epidemiology.
- 244

245 Overall, we observed a significant increase in antibody levels measured in the mucosal lining fluid of the index cases, with a timing that is similar to what has previously been described for serum and 246 247 saliva <sup>6,26,27</sup>. Mucosal IgG and IgM antibody responses measured against the three viral antigens 248 correlated strongly with serum antibody levels, but were weaker for IgA, measured at 28-40 days PSO. This has previously been described for saliva<sup>26,27,31</sup>. A key finding of this study is that the mucosal IgA 249 response against RBD showed the strongest relation to resolution of systemic disease symptoms. This 250 phenomenon has also been addressed by Butler *et al.*<sup>32</sup> in a smaller cohort (n=20). They found that 251 252 strong mucosal IgA responses against SARS-CoV-2 was related to neutralizing activity and that 253 elevated levels of mucosal neutralization were associated with mild and moderate symptoms. This neutralizing activity of IgA has also been described in a bigger study that mainly focused on serum<sup>33</sup>. 254 255 Another study in one family showed spiking salivary IgA levels at the time of symptom resolution, 256 while serum antibody levels remained low.<sup>3</sup> Our larger study, including for the first time the dynamic measurement of the lining fluid of the upper respiratory tract, clearly shows the relation of mucosal 257 antibodies with a decrease in symptom burden. Nevertheless, we did not measure neutralizing activity, 258 259 and found that other mucosal responses against S and RBD also contributed to a reduction of systemic 260 disease symptoms. Another significant finding was the negative correlation between viral load and 261 mucosal IgM against RBD and S, measured at study start, suggestive of a neutralizing role of mucosal 262 IgM, although other possible explanations, like pre-existing T-cell immunity cannot be excluded<sup>34,35</sup>.

263

Thus, a strong mucosal antibody response might play an important role in preventing severe disease, 264 by reducing the systemic symptoms and reducing viral load. Patients with severe COVID-19 are 265 sometimes treated with convalescent plasma from patients who have recovered from COVID-19<sup>36,37</sup>. 266 267 Given their multimeric nature, IgM and IgA antibodies specific for RBD are likely to neutralize SARS-CoV-2 particles and strong neutralizing capacity has been described previously for both 268 isotypes<sup>33,38</sup>. Therefore we propose that these antibodies should be included in the quality evaluation of 269 270 convalescent plasma. Moreover, monitoring of SARS-CoV-2-specific antibody concentration in MLF 271 in patients receiving convalescent plasma may yield important insights into which doses are required to reach sufficient concentrations at the primary site of infection. Intranasal administration of SARS-272 273 CoV-2 specific IgM or IgA in patients recently diagnosed with COVID-19 may provide an additional 274 treatment option.

275 Because we measured the mucosal response of three antibodies against three different antigens, we 276 were able to describe correlations between these antigen/isotype combinations. We found that there 277 was a coherent antibody production against S and RBD early in the infection. Correlations between S 278 and RBD with the N antigen were significantly less pronounced, and only emerged later in the 279 infection, mostly for IgG. This indicates that the antibody response to the nucleocapsid antigen follows a different track after infection, than S and RBD, which was also seen in previous studies<sup>26,27,31</sup>. This 280 281 variation in the antibody response composition could be explained by the cross-reactivity with other 282 seasonal coronaviruses. Previous exposure with these coronaviruses could elicit a booster response 283 instead of a primary immune response during SARS-CoV-2 exposure, explaining the presence of IgG 284 and IgA and absence of IgM, which has the strongest response after primary exposure. Next to this, 285 the release of N-proteins requires the lysis of virally infected cells, as it encapsulates the viral RNA. This could explain the difference in timing and the generally low mucosal antibody responses against 286

- 287 N, as all our participants developed mild disease.
- 288

The ability to measure the mucosal antibody response over a longer period of time in an easy, noninvasive manner allowed us to identify cases among the household members that were not picked up by PCR-testing at a single timepoint only. When we performed the study, we were unable to collect additional samples for viral PCR due to shortages in swabs and transport medium, limiting our ability to fully study the dynamic interactions between viral infection and antibody responses, and calculate the sensitivity of the antibody measurements in diagnosing infection in comparison to PCR. We observed a very high proportion of cases among the household contacts (54.7%), which is much

higher than previously reported  $(11-37\%)^{39-41}$ . This can partly be explained by the fact that not all the index cases were the primary case, due to the restricted PCR testing on specific risk-groups at the time the study was performed. By using the households' primary case reporting, the secondary attack rate

(SAR) was lowered to 49.6%. The fact that we still find a higher SAR than described in previous

300 studies may be explained by the fact that almost all household transmission studies to date identified

301 cases based on PCR positivity only, and thus underestimate the true number of cases within a cluster.

302 PCR testing is prone to false negative results due to it being a one-time measurement, its dependency

303 on the time of sampling in relation to the infection, and the chance of errors during sample collection.

304 By combining PCR, serology and mucosal data, we were able to identify an additional 27 cases,

increasing the total number of contact cases by a third. Although we used the mucosal antibody levelsas an exploratory case-identification tool and used PCR and serology for most of the case

identifications, the majority of serum and PCR positive contacts also had mounted a mucosal antibody
 response towards the end of the follow-up (<u>Table S2</u>). These results suggest that mucosal lining fluid

309 could be used as a non-invasive way to measure disease exposure in a community setting, and as a tool

to identify the primary case in a household.

Children were initially thought to be play less of a role in SARS-CoV-2 infection and transmission, 312 because of a lower expression of ACE2 and the high frequency of asymptomatic infections compared 313 to adults <sup>42-44</sup>. This notion has been debated in research<sup>11,45-48</sup>, and is critical for making decisions 314 related to epidemic control measurements, like school-closure. In our study, we found that children 315 316 <12 years had a similar probability to become infected as adults. Almost half of the child cases in our 317 study were asymptomatic, their viral load at study start was similar to that of adults, and other studies have shown that 40-80% of transmission events take place before symptom onset <sup>49-51</sup>. A study looking 318 at the viral shedding of asymptomatic, presymptomatic and symptomatic children did not find a 319 320 difference in viral shedding between these groups<sup>52</sup>. Together, these findings imply that children may 321 play a larger role in transmission of SARS-CoV-2 than is currently thought. A prospective cohort 322 study in which MLF samples are collected irrespective of symptom presentation would provide more insight in whether (asymptomatic) infections in children are an important driver of household 323 transmission or not. Since collection of MLF for antibody analysis is rapid, non-invasive and can be 324 done by study participants in the absence of health care professionals, such studies including repetitive 325 326 sampling are feasible in this age group.

327

Our study has several limitations. First, the starting point for our study was the inclusion of healthcare workers, most of whom were female, and not entirely representative for the larger population. It should be noted that this study was performed during the first wave in March-April of 2020, when all

schools in the Netherlands were closed (**Figure 1b**), minimizing contacts between children and thus

making it hard to study the role of child-child contacts in the transmission of SARS-CoV-2. Lastly,

additional mucosal lining fluid measurements would have enabled more advanced modelling of the

334 mucosal antibody trajectories, especially in the household contacts.

335

This study provides an example of the unique possibilities of studying mucosal antibody trajectories. It provides essential new insights into the mucosal antibody kinetics after a SARS-CoV-2 infection, and uncovers novel relations with viral load and symptom resolution. Furthermore, the study design and analysis strategy presented here can be used as a blueprint for follow-up investigations not only for COVID-19, but also for other infectious diseases. The ability to collect repetitive mucosal antibody samples in a non-invasive manner removes an important obstacle for use in age groups that are normally difficult to sample, such as children.

#### 343 ONLINE METHODS

#### 344 **<u>Recruitment</u>**

345 This observational prospective cohort study was conducted among COVID-19 cases with a laboratory 346 confirmed infection, as well as their household members that remained in home quarantine at the same 347 address. The study was conducted in accordance with the provisions of the Declaration of Helsinki 348 (1996) and the International Conference on Harmonization Guidelines for Good Clinical Practice. The 349 study was approved by the local medical research ethics committee and is registered with 350 ClinicalTrials.gov (NCT04590352; ethical committee reference NL73418.091.20). All index cases in 351 this study were healthcare workers (HCW) from three hospitals (Radboudumc, CWZ and Rijnstate) in 352 the provinces of Gelderland in the Netherlands, with a confirmed SARS-CoV-2 infection. Study 353 participants were included from the 26<sup>th</sup> of March 2020 until the 15<sup>th</sup> of April, when the inclusion number of 50 households was reached. Participants were introduced to the study through the 354 occupational health and safety services (OHS) of the participating hospitals. HCWs were included if 355 they had a positive Polymerase Chain Reaction test (PCR-test) for the SARS-CoV-2 virus, tested and 356 judged by the OHS of their hospital, with a positive indication for home isolation, and had at least two 357 358 household members willing to participate.

359

#### 360 Study design

Before the first home visit, all index cases of the family had a telephone interview, where they were 361 362 asked about their first day of symptom onset, whether they were in isolation from the rest of the 363 household, whether physical contact was restricted with other household members, whether they were 364 still symptomatic, and whether they thought they were the primary case in the household. Households 365 were visited within 1-2 days of a positive PCR in the index case. Following informed consent, 366 nasopharyngeal and oropharyngeal swabs were taken for viral PCR, as per diagnostic guidelines<sup>53</sup>. A 367 nasal mucosal lining fluid (MLF) sample was obtained from all participants by the use of the Nasosorption<sup>TM</sup> FX i nasal sampling device (Hunt Developments, UK). A synthetic absorptive matrix 368 369 (SAM) strip was gently inserted into the nostril of the participant and placed along the surface of the 370 inferior turbinate. The index finger was lightly pressed against the side of the nostril to keep the SAM strip in place and to allow MLF absorption for 60 seconds, after which the SAM strip was placed back 371 372 in the protective plastic tube. Participants were instructed on how to self-sample MLF at home.

373 Finally, participants were asked about their symptoms of that day.

374 Participants were followed up for approximately 28 days, starting on the day of the first home visit

(day 0) and ending on the last home visit (day 28-33). This range in the last visit was due to logistical

difficulties during the summer holidays; 14 index cases were visited on their day 29, three on day 30,

five on day 31, four on day 32 and one on day 33. All participants registered their symptoms for 28

days. During follow-up, clinical symptoms were registered three times daily and MLF was collected at

three different study days via self-sampling. For the index case, MLF was collected on day 0, 3, 6 and

- 28-33 and for the household contacts this was on day 0, 7, 14 and 28-33 (Figure 1c). Self-sampled
- 381 MLF samples were stored in biosafety bags in the participants' own freezer (temperature around -20
   382 °C).
- 383 At the final home visit, MLF samples were picked up and transported to the Radboudumc on dry ice,
- 384 where it was stored at -80°C until further testing. For antibody analysis, Nasosorption<sup>TM</sup> FX i nasal
- sampling devices were thawed on ice, after which the synthetic adsorptive matrix (SAM) was removed
- using sterile forceps. The SAM was placed in a spin-X filter Eppendorf tube with 300uL of elution
- buffer (PBS/1% BSA) for a minimum of 10 minutes, followed by centrifugation at 16000xg for 10
- 388 minutes at 4°C. To prevent unspecific binding, the spin-X filter columns were pre-incubated with the
- blocking buffer for 30 minutes. The filter cups were then removed from the Eppendorf tubes using
- 390 sterile forceps. To inactivate live SARS-CoV-2, the eluate was incubated for a minimum of 45
- 391 minutes at 56 °C, spun down, aliquotted and stored at -20°C for further testing.
- Finger-prick blood (~0.3 ml) was collected from all participants consenting to the finger-prick at day
- 28 by the use of a sterile disposable lancet device (BD Microtainer Lancet) and a sterile capillary tube.
- Blood samples were kept at room temperature until processing at the Radboudumc laboratory site,
- after which serum was stored at  $-20^{\circ}$ C until further testing.
- 396 All collected symptom diaries were digitalized into Castor EDC, clinical trial software for electronic
- 397 data capture and clinical data management.
- 398

### 399 Sample analysis

#### 400 Detection of SARS-CoV-2

- 401 Presence or absence of SARS-CoV-2 and viral copy number per ml was determined on the combined
- 402 nasopharyngeal and oropharyngeal swab, using a PCR protocol that was developed at the
- 403 Radboudumc Medical Microbiology Laboratory. Nasopharyngeal and oropharyngeal swabs were
- 404 collected in GLY medium and stored at -80°C untill processing. Samples were thawed, vortexed and
- 405 500 ul of sample was lysed in 450 ul MagNAPure Lysis/binding buffer (Roche). An ivRNA internal
- 406 extraction control was added and samples were extracted on the automated MagNAPure LC2.0 system
- 407 using the MagNAPure LC Total Nucleic Acid isolation kit High Performance (Roche). Samples were
- 408 eluted in 50 ul of which 5 ul was used in the RT-qPCR using the Luna Universal Probe One-Step RT-
- 409 qPCR kit (NEB) with 400 nM E-gene primers (FW: 5'- acaggtacgttaatagttaatagcgt-3' RV: 5'-
- 410 atattgcagcagtacgcacaca-3') and 200 nM E-gene probe (5'-FAM-
- 411 ACACTAGCCATCCTTACTGCGCTTCG-BHQ1-3' (Biolegio)) on a CFX96 Real-Time PCR
- 412 Detection System (BioRad). Transcript quantities were calculated using a 10-fold dilution series of E-
- 413 gene ivRNA. The extraction efficiency was checked in a separate RT-qPCR using the Luna Universal
- 414 Probe One-Step RT-qPCR kit (NEB) with primers targeting the ivRNA that was added prior to
- 415 extraction.
- 416 Antibody measurements

- 417 For antibody analysis, a fluorescent-bead-based multiplex immunoassay (MIA) was developed. The
- 418 stabilized pre-fusion conformation of the ectodomain of the Spike protein (amino acids 1 1,213)
- 419 fused with the trimerization motif GCN4 (S-protein) and the receptor binding domain of the S-protein
- 420 (RBD) as previously described by Wang C. et al.<sup>54</sup>, and the Nucleocapsid-His recombinant Protein (N)
- 421 (40588-V08B, Sino Biologicals), were each coupled to beads or microspheres with distinct
- 422 fluorescence excitation and emission spectra, essentially as described in the paper by den Hartog *et* 423  $al.^{55}$
- 424 A total of six reference serum samples were selected from PCR confirmed COVID-19 patients with
- 425 varying immunoglobulin G (IgG) concentrations, and pooled to create standard curves for IgG, IgA
- 426 and IgM. Next to this, four different samples from the same cohort were used as quality control
- 427 samples. As negative control samples, we used historical serum (n=32) and MLF (n=17) samples
- 428 collected prior to the SARS-CoV-2 pandemic.
- 429 MLF samples were diluted 1:5 in assay buffer (PBS/1% BSA/0.05% tween-20) and serum samples
- 430 were diluted 1:500 in assay buffer, incubated with antigen-coated microspheres for 30 minutes at room
- 431 temperature while shaking at 450 rpm. Following incubation, the microspheres were washed two times
- 432 with PBS, incubated with phycoerythrin-conjugated goat anti-human, IgG (Jackson Immunoresearch,
- 433 109-116-170), IgM (Southern Biotech, 2022-09) and IgA (Southern Biotech, 2052-09) for 20 minutes
- 434 and washed twice. Data were acquired on the Luminex FlexMap3D System. Validation of the
- 435 detection antibodies was obtained from a recent publication using the same antibodies and the same
- 436 assay<sup>55</sup>, and specificity was checked using rabbit anti-SARS SIA-ST serum.
- 437 S- and N-coupled microspheres were combined to measure antibodies directed against multiple
- 438 antigens (or epitopes) in one single sample. Since antibodies against the S-protein and RBD may
- 439 compete for the same epitopes, antibody binding to RBD was measured separately. Using different
- 440 conjugates, IgG, IgA, and IgM-specific antibodies concentrations were measured in MLF and serum.
- 441 MFI was converted to arbitrary units (AU/ml) by interpolation from a log-5PL-parameter logistic
- standard curve and log-log axis transformation, using Bioplex Manager 6.2 (Bio-Rad Laboratories)
- software and exported to R-studio. Negative control samples (MLF and serum) were used to filter out
- 444 background signal in the antibody measures. The MLF samples originated from the KIRA-study
- 445 performed at the Radboudumc, in which healthy healthcare workers are vaccinated against pertussis as
- 446 per routine care, and gave consent to the use of the MLF samples for other research. The serum
- samples originated from the Radboudumc Biobank, that allows the use of serum samples for research
- 448 as long as privacy of the donors is guaranteed. The standard dilution range plus four quality control
- samples were added to each plate.
- 450

## 451 Symptom categorization

To analyse the relation between symptom clearance in index cases and the mucosal antibody response, we categorized our set of symptoms into three categories, based on their clinical presentation. This

we categorized our set of symptoms into three categories, based on their ennear presentation. In

- 454 resulted in a set of 23 symptoms, which were categorized into three categories, i.e. respiratory
- 455 symptoms (RS) systemic disease symptoms (SDS), and gastrointestinal symptoms (GS). RS includes
- 456 chest pain, sneezing, nose bleeding, pain when breathing, coughing with mucus, dyspnoea, sore throat,
- 457 loss or change of taste/smell (dysnosmia), coughing, and rhinorrhoea. SDS includes dizziness,
- 458 headache, fever, temperature, chills, joint pain, muscle pain, swollen lymph nodes and low appetite.
- 459 GS includes vomiting, diarrhoea, and nausea. Because fatigue was reported in almost all cases, we did
- 460 not categorize it into one of the symptom categories.
- 461

#### 462 <u>Case definition and cluster identification</u>

463 For analysis of SARS-CoV-2 exposure within households, we categorized the household contacts into 464 cases and controls. Cases were defined as being either PCR positive at study start and/or seropositive for IgA, IgG or IgM against S at the end of follow-up. PCR positivity was set on a Ct value<36, which 465 corresponds to a viral load of at least 10<sup>3</sup> copies/ml extracted sample. The seroconversion threshold 466 was based on the mean + 2\*SD of the historic negative control samples, which were collected before 467 SARS-CoV-2 was introduced in the Netherlands. Additionally, we used a Naïve Bayesian 468 469 probabilistic model (R-package "naivebayes", with prior probabilities derived as the class proportions 470 for the training set, and Laplace smoothing set at 1) to identify cases within the PCR/seronegative 471 contacts by the anti-S MLF antibody response on day 28. Mucosal antibody levels from PCR positive cases were used as positive controls; mucosal antibody levels from the historic cohort samples as 472 473 negative controls. These values were used to train the probabilistic model, after which the model was 474 applied to the PCR/seronegative contacts.

475

#### 476 Statistical analyses

477 Analysis of Luminex data was performed with Bio-Plex 200 in combination with Bio-Plex manager 478 software (Bio-Rad Laboratories, Hercules, CA). Demographical data was exported from Castor EDC, 479 and double checked with the paper records by two members of the research team. All statistical 480 analyses were performed using the Rstudio environment, with libraries 'stats' (hypothesis tests and correlations), "naivebayes" for the naïve Bayes classification, "lme4" <sup>56</sup>, "lmerTest" <sup>57</sup> for mixed-481 effects modelling and associated p-values, and "survival" <sup>58</sup> for Kaplan-Meier survival analysis. The 482 483 libraries "survminer" and "ggplot2" were used for visualization. Changes in serum or mucosal 484 antibodies compared to negative controls were tested using a two-tailed paired Wilcoxon signed rank test, and then corrected for multiple testing with the Benjamini-Hochberg method <sup>59</sup>. Statistical 485 parameters including the sample sizes, measures of distribution, and p-value thresholds for 486 487 significance are reported directly in the figures and figure legends. In order to determine if a sample was seropositive for a given combination of antigen and antibody isotype, a cut-off value (mean + 2488 489 standard deviations) was calculated from the negative control samples. Samples above this threshold 490 were classified as seropositive for that antigen and isotype combination. Samples that were

491	seropositive for any of the antibodies tested were classified as such ("anySero", Figure 2A). Where
492	correlations are presented, the spearman correlation coefficient and associated p-value were calculated.
493	The time at which a subject became symptom-free was calculated as the last day that individual
494	showed symptoms for that category, plus one day. The probability of becoming symptom-free was
495	estimated using Kaplan-Meier's method, and the hypothesis testing was performed using log-rank test.
496	In order to estimate the effect of patient characteristics and antibodies on symptoms over time, we
497	constructed a mixed-effects model. For each subject and for each timepoint, we added together the
498	number of complaints per symptom category. We specified a mixed-effects model per symptom
499	category with symptoms as the response and time since symptom onset (POS), age, and sex, as
500	explanatory variables. We also added POS and Sample_ID as random effects. The formula for the
501	model (in R notation):
502	
503	Symptom_count ~ POS + Age + Sex + (POS   Sample_ID)
504	
505	In order to determine the effect of antibodies on the symptom response, the model above was updated
506	in a univariate fashion with each antibody measurement as a covariate. The formula of the updated
507	model:
508	
509	Symptom_count ~ POS + Age + Sex + Antibody + (POS   Sample_ID).
510	Estimates for the covariates, as well as 95% confidence intervals and p-values (Satterthwaite's
511	approximation to degrees of freedom) were extracted and plotted.
512	
513	FUNDING
514	This study was funded by the Laboratory of Medical Immunology, Radboud university medical center.
515	
516	DATA AND CODE AVAILABILITY STATEMENT
517	The data and R-code that support the findings of this study are available from the corresponding
518	author upon reasonable request.
519	
520	CONTRIBUTORS
521	Conceptualization: D.A.D and M.I.J.; investigation: J.F., D.A.D., R.P., J.R., D.T., and M.B.; lab
522	processing: J.F., R.P., D.A.D., K.L., E.S., and C.E.GJ.; formal analysis: J.F. and J.G.; writing-
523	original draft preparation: J.F., and J.G.; writing-review and editing: J.G, D.A.D., T.B., M.A.H.,
524	M.I.J., and R.P.; resources: F.J.K, BJ.B., N.GB, C.D., and M.NF.; and supervision: D.A.D.
525	
526	DECLARATION OF INTERESTS
527	There are no competing interests to be declared.

## 528 ACKNOWLEDGEMENTS

- 529 We would like to thank all MuCo study participants for their willingness to participate and their
- support for the study. Additionally, we thank M. Boonstra, M. Blok, D. van der Giessen, E. Lenssen,
- E. Reuvers, M. Roek and E. Wijnhoven for assisting with performing the first home visit, H. Lyoo
- from Utrecht university for experimental assistance, J. Heijnen, M. Dautzenberg, and A. Voss for
- recruiting participants from the occupational health and safety officers at Rijnstate and CWZ
- bospitals, and the respective medical microbiology departments involved in PCR testing of hospital
- 535 employees.
- 536
- 537
- 538

#### 539 FIGURE LEGENDS

Figure 1. Flow diagram and study procedures. a) Flow diagram describing the recruitment of 540 541 households, sample sizes, and study outcomes. We initially contacted 97 index cases that were tested 542 positive for SARS-CoV-2. After exclusion of cases that did not meet the inclusion criteria or did not 543 consent, 50 index cases and their household contacts (N=137)were recruited. Mucosal lining fluid 544 (MLF) antibodies were analysed as a primary outcome in both indexes and household contacts. 545 Secondary analyses (correlation of MLF antibodies with viral load and symptoms, serology, 546 estimation of SARS-CoV-2 exposure) were performed. b) Study timeline, with respect to the number 547 of hospitalizations due to COVID-19 over time and COVID-19 control measures in the 548 Netherlands<sup>60,61</sup>. The first home visit was conducted at the peak of hospitalizations at March 26, and 549 the last visit was one day after the reopening of primary schools, at May 13. c) Overview of the study 550 design and measurements. Home visits were initiated after the index was tested positive for SARS-551 CoV-2 by PCR, to collect naso- and oropharyngeal swabs for viral load determination as well as nasal MLF samples. Subsequent MLF samples were collected and stored by the participants, who also 552 553 completed a daily symptom survey. At the end of the study, blood samples were collected for 554 serological analyses. 555 556 Figure 2. Serum antibody responses against SARS-CoV-2 in COVID-19 patients and household 557 558 contacts. a) Seroconversion heatmap for index cases (N=50) and contacts (N=129) for each antigen 559 and antibody isotype measurement, as well as seroconversion rate for any single antibody

560 measurement (anySero). Seroconversion threshold was calculated as the mean of the controls plus

561 2\*standard deviation. b) Serum antibody responses against SARS-CoV-2 in COVID-19 in index cases

562 correlated with mucosal antibody responses. IgM, IgG, and IgA antibody responses against SARS-

563 CoV-2 spike protein (S), receptor binding domain (RBD) and nucleocapsid (N) were measured in sera

or in mucosal lining fluid at the end of the study. Antibody levels are expressed as a ratio compared to

the mean of pre-corona samples (relative ratio). Data are shown for index cases (N=50). Spearman

566 correlations were calculated and p-values are reported directly in the figure.

567

564

568

#### 569 Figure 3. Mucosal antibody responses during SARS-CoV-2 infection in index cases (N=49). a)

570 IgM, IgG and IgA antibody responses against SARS-CoV-2 spike (S), receptor binding domain (RBD)

571 or nucleocapsid (N) collected in mucosal lining fluid at d0 were correlated with days since symptom

572 onset (PSO) and viral load. Spearman correlations were calculated, \* p <0.05, \*\*p<0.01, \*\*\* p<0.001.

573 p-values of borderline significant tests are reported directly in the figure. **b**) Longitudinal mucosal

antibody responses to S, RBD and N, plotted relative to the days PSO. Pre-SARS-CoV-2 controls are

575 presented in the grey boxplots for comparison (n=17). Values within each timeframe were compared

with the controls with the Wilcoxon-signed rank test. A non-parametric Loess curve is shown as red
line to visualize the trend over time. Measurements from the same individual are connected with a
grey line. c) Antibody measurements within the depicted timeframes were correlated with each other.
Spearman correlation coefficient is presented.

- 580
- 581

582 Figure 4. Influence of age and mucosal antibody levels on the progression of systemic and respiratory COVID-19 symptoms. a) The number of respiratory (RS) and systemic disease (SDS) 583 584 symptoms were recorded for index cases (N = 49) for each day during the 28 day study period. Data 585 are plotted relative to the time of symptom onset and values were binned into 3-day time frames. A 586 non-parametric loess curve is shown as a red (SDS) or blue (RS) line in order to visualize the trend 587 over time. b) A linear mixed-effect model (MEM) was fit to the data per symptom group. The 588 response was specified as the number of symptoms on a given day, and explanatory fixed effects variables were: day since symptom onset, age, and sex. Time since symptom onset was also specified 589 590 as a random slope, and Sample ID as a random intercept. A significant effect of age (p = 0.0165) was 591 demonstrated for RS. Predicted symptom values from the model are plotted against index case age 592 with 95% confidence interval bands. c) Longitudinal mucosal antibody measurements were added as 593 fixed effect variables in a univariate fashion to the MEM from b). The predicted change in symptoms 594 per unit increase of antibody signal is presented with 95% confidence intervals, and p-values for the 595 association are plotted on the right (\* p <0.05; \*\* p<0.01; \*\*\* p<0.001).

- 596
- 597

598 Figure 5 Identification of household contact cases and assessment of their mucosal SARS-CoV-2 599 antibody responses. a) Contact cases were classified into case or non-case first by their PCR result on 600 enrolment, followed by seroconversion for either IgM, IgG or IgA against the S-protein, and mucosal 601 antibody levels for either IgM, IgG or IgA against the S-protein at the end of the follow-up. The PCR 602 positive threshold was set at a Ct value <36. The seroconversion threshold was based on the mean + 603 2\*SD of the log2-transformed pre-SARS-CoV-2 control samples. To identify cases based on mucosal 604 antibodies against S, we used a naive Bayes model that was trained by the mucosal antibody 605 measurements of the positive study participants (cases) and the pre-SARS-CoV-2 control samples 606 (controls). b) Contacts were classified by their household as either the primary (N=9) or a non-primary 607 (N=58) case, based on time of symptom onset. Mucosal antibody responses of the primary household 608 contact cases collected at d0 were correlated with viral load. Spearman correlations were calculated, \* p <0.05, \*\* p<0.01, \*\*\* p<0.001. p-values of borderline significant tests are reported directly in the 609 figure. c) IgM, IgG and IgA antibody responses against Spike protein (S), receptor binding domain 610 (RBD) and nucleocapsid (N), measured in mucosal lining fluid. Data are plotted relative to the time of 611 612 symptom onset of the index case in the respective household, and pre-SARS-CoV-2 control samples

- are presented for comparison. A non-parametric loess curve is shown as a red (primary cases) and ablue (non-primary cases) line to visualize the trend over time.
- 615
- 616

#### Figure 6. SARS-CoV-2 infection, viral load and number of symptoms of contact cases, split into 617 618 four age groups. a) Proportion of infected household contacts per age group. Sixteen out of 33 619 primary school-age children (1-12y) were infected (48%), 13 out of 23 children aged 13-18y (56%), 27 out of 50 adults aged 19-49 years (54%) and 19 out of 31 contacts older than 50 years (61%). b) 620 621 Proportion of asymptomatic disease among household cases (N=75) at study enrolment within each 622 age category. Seven of the children below 12 years were asymptomatic (44%), two of the children up 623 to 18 years (15%), seven of the adults up to 49 years (28%) and two of the contacts older than 50 years (11%). c) The correlation between the total number of reported symptoms and the age of the infected 624 household contacts. Pearson's correlation and significance is depicted in the figure. The shape of the 625 datapoints represents the method by which a contact was classified as a case and the color of the 626 627 datapoints shows the viral load at study start. 628

629

#### 630 Figure S1. Serum antibody responses against Sars-CoV-2 in COVID-19 patients and household

631 contacts. IgM, IgG, and IgA serum antibody responses against Sars-CoV-2 spike protein (S), receptor

binding domain (RBD), or nucleocapsid (N). Data are shown for pre-SARS-Cov-2 control samples

633 (N=32), index cases (N=50), or household contacts (N=129). Antibody levels are expressed as a ratio

- 634 compared to the mean of the controls (relative ratio) and values of indexes and contacts were

and a threshold for seroconversion (dotted line) was calculated based on the mean + 2\*sd of thecontrol samples.

- 638
- 639

#### 640 Figure S2. Timing of COVID-19 patient recruitment and sample measurements relative to

**symptoms onset. a)** The graph shows the cumulative percentage of households (N=50) included at a

- 642 given time post symptom onset. b) Overview of the measurements made for the index cases relative to
- 643 the reported first day of symptom onset. Each line represents one participant.
- 644
- Figure S3. SARS-CoV-2 viral load at different days post symptom onset. Index cases (N=49) were
   asked when their symptoms started, and viral load was measured at study start. Individuals are binned
- together based on their reported symptom onset, relative to the study start. The y-axis shows the
- 648 average viral load in log10 copies/ml extracted sample.
- 649

Figure S4. Clinical presentation of mild COVID-19 disease. a) Index cases (N = 49) completed a 650 daily symptom survey covering 23 symptoms for 28 days during the study period. The number of 651 652 index cases that reported a given symptom at any time during the study period is presented. Symptoms 653 were categorized into either respiratory symptoms (RS), systemic disease symptoms (SDS), or 654 gastrointestinal symptoms (GS). Fatigue was not categorized. b) Cumulative symptoms per symptom 655 group for each study day are plotted for each index case. Data are represented since the time of 656 symptom onset. A window depicts the study period for a given index case. c) Symptom durations were 657 calculated for RS and SDS, and compared using a Kaplan Meier analysis. The probability of becoming 658 symptom-free at a given time post-symptom onset is depicted. The log-rank p-value represents the 659 statistical difference between resolution of SDS and RS.

- 660
- 661

#### 662 Figure S5. Mixed-effects modelling of longitudinal symptom data in COVID-19 patients. The

number of respiratory (RS) and systemic disease (SDS) symptoms were determined for index cases (N
= 49) for each day during the 28 day study period. Data are represented relative to the time of
symptom onset. A linear mixed-effect model was fit to the data per symptom group. The response was
specified as the number of symptoms on a given day, and explanatory fixed effects variables were: day
since symptom onset, age, and sex. Time since symptom onset was also specified as a random slope,
and Sample ID as a random intercept. Datapoints are plotted per day and joined by a faded line,
predicted values from the mixed effects model are plotted on top as solid straight lines.

- 669 predicted values from the mixed-effects model are plotted on top as solid straight lines.
- 670
- 671

#### 672 Figure S6. Viral load and anti-Spike serum antibody concentrations in household contact cases

of different age categories. a) Viral load at study enrolment, depicted for the PCR positive household

cases (n=46). The y-axis shows the average viral load in log10 copies/ml extracted sample of the

675 contact cases, the x-axis shows the four different age categories. b) Serum anti-Spike protein levels at

the end of the study, for IgA, IgM and IgG, in each age category. Serum antibody levels are depicted

- as the log10 antibody concentration in AU/ml. Only infected household members were selected
- 678 (n=75).

medRxiv preprint doi: https://doi.org/10.1101/2021.02.02.21250910; this version posted February 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

# perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

#### 679 REFERENCES

680 Lewis NM, Duca LM, Marcenac P, et al. Early Release-Characteristics and Timing of Initial 1. 681 Virus Shedding in Severe Acute Respiratory Syndrome Coronavirus 2, Utah, USA.

682 Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 infections in households-2. 683 Tennessee and Wisconsin, April–September 2020. Morbidity and Mortality Weekly Report 2020; **69**(44): 1631. 684

685 3. Tosif S, Neeland MR, Sutton P, et al. Immune responses to SARS-CoV-2 in three children of 686 parents with symptomatic COVID-19. Nature Communications 2020; 11(1): 5703.

- 687 4. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients 688 with COVID-2019. Nature 2020.
- 689 Lee S, Kim T, Lee E, et al. Clinical Course and Molecular Viral Shedding Among Asymptomatic 5. 690 and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the 691 Republic of Korea. JAMA Intern Med 2020.
- 692 6. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal 693 saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational 694 cohort study. Lancet Infect Dis 2020.
- 695 7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 696 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center 697 for Disease Control and Prevention. Jama 2020.
- 698 8. Kim G-u, Kim M-J, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic 699 patients with mild COVID-19. Clinical Microbiology and Infection 2020.
- 700 9. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. 701 Ann Intern Med 2020.
- 702 10. RIVM. Epidemiologische situatie COVID-19 in Nederland: Rijksinstituut voor Volksgezondheid 703 en Milieu, 2020.
- 704 11. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles' heel of current 705 strategies to control COVID-19. Mass Medical Soc; 2020.
- 706 12. WHO. Public health surveillance for COVID-19 WHO, 2020.
- 707 13. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and 708 transmission in a skilled nursing facility. New England journal of medicine 2020.
- 709 14. Mizrahi B, Shilo S, Rossman H, et al. Longitudinal symptom dynamics of COVID-19 infection in 710 primary care. medRxiv 2020.
- 711 15. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine 712 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
- 713 South Africa, and the UK. The Lancet 2020.
- 714 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 16. 715 vaccine. New England Journal of Medicine 2020.
- 716 17. Dutta NK, Mazumdar K, Gordy JT. The nucleocapsid protein of SARS–CoV-2: a target for 717 vaccine development. Journal of virology 2020; 94(13).
- 718 18. McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-CoV-2 719 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI insight 720 2020; 5(18).
- 721 19. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel 722 coronavirus disease 2019. Clin Infect Dis 2020.
- 723 20. Carsetti R, Zaffina S, Piano Mortari E, et al. Spectrum of innate and adaptive immune 724 response to SARS CoV 2 infection across asymptomatic, mild and severe cases; a longitudinal cohort 725 study. medRxiv 2020.
- 726 Rijkers G, Murk J-L, Wintermans B, et al. Differences in antibody kinetics and functionality 21. 727 between severe and mild SARS-CoV-2 infections. medRxiv 2020.
- 728 22. Marklund E, Leach S, Axelsson H, et al. Serum-IgG responses to SARS-CoV-2 after mild and 729 severe COVID-19 infection and analysis of IgG non-responders. medRxiv 2020.

medRxiv preprint doi: https://doi.org/10.1101/2021.02.02.21250910; this version posted February 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

730 23. Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing 731 antibody responses that are stable for at least three months. *medRxiv* 2020. 732 24. Du L, Zhao G, Lin Y, et al. Intranasal vaccination of recombinant adeno-associated virus 733 encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) 734 spike protein induces strong mucosal immune responses and provides long-term protection against 735 SARS-CoV infection. J Immunol 2008; 180(2): 948-56. 736 25. Lee J-S, Poo H, Han DP, et al. Mucosal Immunization with Surface-Displayed Severe Acute 737 Respiratory Syndrome Coronavirus Spike Protein on <em>Lactobacillus casei</em> Induces 738 Neutralizing Antibodies in Mice. Journal of Virology 2006; 80: 4079-87. 739 26. Pisanic N, Randad PR, Kruczynski K, et al. COVID-19 serology at population scale: SARS-CoV-2-740 specific antibody responses in saliva. . J Clin Microbiol; (JCM.02204-20). 741 Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-27. 742 CoV-2 spike antigens in COVID-19 patients. *Science immunology* 2020; 5(52). 743 28. Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody secretion specific to 744 SARS-CoV-2 during mild versus severe COVID-19. *bioRxiv* 2020. 745 29. Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses 746 in SARS-CoV-2 infection. medRxiv 2020. 747 Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 30. 748 1,420 European patients with mild-to-moderate coronavirus disease 2019. Journal of internal 749 medicine 2020. 750 31. Faustini SE, Jossi SE, Perez-Toledo M, et al. Detection of antibodies to the SARS-CoV-2 spike 751 glycoprotein in both serum and saliva enhances detection of infection. medRxiv 2020. 752 Butler SE, Crowley AR, Natarajan H, et al. Features and Functions of Systemic and Mucosal 32. 753 Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. medRxiv 2020. 754 33. Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response 755 to SARS-CoV-2. Science Translational Medicine 2020. 756 34. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of 757 COVID-19 and SARS, and uninfected controls. Nature 2020; 584(7821): 457-62. 758 Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in 35. 759 unexposed humans. Science 2020; 370(6512): 89-94. 760 36. Li L, Tong X, Chen H, et al. Characteristics and serological patterns of COVID-19 convalescent 761 plasma donors: optimal donors and timing of donation. Transfusion 2020; 60(8): 1765-72. 762 37. Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible 763 mechanisms of action. Autoimmunity Reviews 2020; 19(7): 102554. 764 38. Gasser R, Cloutier M, Prévost J, et al. Major role of IgM in the neutralizing activity of 765 convalescent plasma against SARS-CoV-2. bioRxiv 2020. 766 39. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of 767 their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet Infectious Diseases 768 2020. 769 40. Koh WC, Naing L, Rosledzana MA, et al. What do we know about SARS-CoV-2 transmission? A 770 systematic review and meta-analysis of the secondary attack rate, serial interval, and asymptomatic 771 infection. medRxiv 2020. 772 Lopez Bernal J, Panagiotopoulos N, Byers C, et al. Transmission dynamics of COVID-19 in 41. 773 household and community settings in the United Kingdom. *medRxiv* 2020. 774 42. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 775 in children and adults. Jama 2020. 776 43. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 777 2020; **145**(6). 778 44. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. Journal of medical 779 virology 2020. 780 45. Dub T, Erra E, Hagberg L, et al. Transmission of SARS-CoV-2 following exposure in school 781 settings: experience from two Helsinki area exposure incidents. *medRxiv* 2020.


medRxiv preprint doi: https://doi.org/10.1101/2021.02.02.21250910; this version posted February 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

782 46. Han MS, Choi EH, Chang SH, et al. Clinical Characteristics and Viral RNA Detection in Children 783 With Coronavirus Disease 2019 in the Republic of Korea. JAMA Pediatrics 2021; 175(1): 73-80. 784 47. Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. The Lancet 785 Infectious Diseases 2020. 786 48. Lee B, Raszka WV. COVID-19 transmission and children: the child is not to blame. Pediatrics 787 2020; 146(2). 788 49. Tindale LC, Stockdale JE, Coombe M, et al. Evidence for transmission of COVID-19 prior to 789 symptom onset. Elife 2020; 9: e57149. 790 50. Cheng H-Y, Jian S-W, Liu D-P, Ng T-C, Huang W-T, Lin H-H. Contact tracing assessment of 791 COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after 792 symptom onset. JAMA internal medicine 2020. 793 Moghadas SM, Fitzpatrick MC, Sah P, et al. The implications of silent transmission for the 51. 794 control of COVID-19 outbreaks. Proceedings of the National Academy of Sciences 2020; 117(30): 795 17513-5. 796 52. Han MS, Choi EH, Chang SH, et al. Clinical characteristics and viral RNA detection in children 797 with coronavirus disease 2019 in the Republic of Korea. JAMA pediatrics 2020. 798 53. Richtlijnen COVID-19. 2020. https://lci.rivm.nl/richtlijnen/covid-19 (accessed January 14 799 2021). 800 54. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. 801 Nature Communications 2020; 11(1): 2251. 802 den Hartog G, Schepp RM, Kuijer M, et al. SARS-CoV-2–Specific Antibody Detection for 55. 803 Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. The 804 Journal of Infectious Diseases 2020; 222(9): 1452-61. 805 56. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using Ime4. arXiv preprint arXiv:14065823 2014. 806 807 57. Kuznetsova A, Brockhoff PB, Christensen RH. ImerTest package: tests in linear mixed effects 808 models. Journal of statistical software 2017; 82(13): 1-26. 809 58. Therneau TM, Grambsch PM. The Cox model. Modeling survival data: extending the Cox 810 model: Springer; 2000: 39-77. 811 59. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful 812 Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 1995; **57**(1): 289-300. 813 Aantal in het ziekenhuis opgenomen patiënten naar datum van ziekenhuisopname. 2020. 814 60. 815 https://www.rivm.nl/coronavirus-covid-19/grafieken (accessed 19 January 2021). Maart 2020: Maatregelen tegen verspreiding coronavirus, intelligente lockdown. 2020. 816 61. 817 https://www.rijksoverheid.nl/onderwerpen/coronavirus-tijdlijn/maart-2020-maatregelen-tegen-818 verspreiding-coronavirus (accessed 19 January 2021).



**Figure 1. Flow diagram and study procedures. a)** Flow diagram describing the recruitment of households, sample sizes, and study outcomes. We initially contacted 97 index cases that were tested positive for SARS-CoV-2. After exclusion of cases that did not meet the inclusion criteria or did not consent, 50 index cases and their household contacts (N=137)were recruited. Mucosal lining fluid (MLF) antibodies were analysed as a primary outcome in both indexes and household contacts. Secondary analyses (correlation of MLF antibodies with viral load and symptoms, serology, estimation of SARS-CoV-2 exposure) were performed. **b)** Study timeline, with respect to the number of hospitalizations due to COVID-19 over time and COVID-19 control measures in the Netherlands60,61. The first home visit was conducted at the peak of hospitalizations at March 26, and the last visit was one day after the reopening of primary schools, at May 13. **c)** Overview of the study design and measurements. Home visits were initiated after the index was tested positive for SARS-CoV-2 by PCR, to collect naso- and oropharyngeal swabs for viral load determination as well as nasal MLF samples. Subsequent MLF samples were collected and stored by the participants, who also completed a daily symptom survey. At the end of the study, blood samples were collected for serological analyses.



**Figure 2. Serum antibody responses against SARS-CoV-2 in COVID-19 patients and household contacts. a)** Seroconversion heatmap for index cases (N=50) and contacts (N=129) for each antigen and antibody isotype measurement, as well as seroconversion rate for any single antibody measurement (anySero). Seroconversion threshold was calculated as the mean of the controls plus 2\*standard deviation. **b)** Serum antibody responses against SARS-CoV-2 in COVID-19 in index cases correlated with mucosal antibody responses. IgM, IgG, and IgA antibody responses against SARS-CoV-2 spike protein (S), receptor binding domain (RBD) and nucleocapsid (N) were measured in sera or in mucosal lining fluid at the end of the study. Antibody levels are expressed as a ratio compared to the mean of pre-corona samples (relative ratio). Data are shown for index cases (N=50). Spearman correlations were calculated and p-values are reported directly in the figure.






Figure 3. Mucosal antibody responses during SARS-CoV-2 infection in index cases (N=49). a) IgM, IgG and IgA antibody responses against SARS-CoV-2 spike (S), receptor binding domain (RBD) or nucleocapsid (N) collected in mucosal lining fluid at d0 were correlated with days since symptom onset (PSO) and viral load. Spearman correlations were calculated, \* p <0.05, \*\*p<0.01, \*\*\* p<0.001. p-values of borderline significant tests are reported directly in the figure. b) Longitudinal mucosal antibody responses to S, RBD and N, plotted relative to the days PSO. Pre-SARS-CoV-2 controls are presented in the grey boxplots for comparison (n=17). Values within each timeframe were compared with the controls with the Wilcoxon-signed rank test. A non-parametric Loess curve is shown as red line to visualize the trend over time. Measurements from the same individual are connected with a grey line. c) Antibody measurements within the depicted timeframes were correlated with each other. Spearman correlation coefficient is presented.





**Figure 4. Influence of age and mucosal antibody levels on the progression of systemic and respiratory COVID-19 symptoms. a)** The number of respiratory (RS) and systemic disease (SDS) symptoms were recorded for index cases (N = 49) for each day during the 28 day study period. Data are plotted relative to the time of symptom onset and values were binned into 3-day time frames. A non-parametric loess curve is shown as a red (SDS) or blue (RS) line in order to visualize the trend over time. **b)** A linear mixed-effect model (MEM) was fit to the data per symptom group. The response was specified as the number of symptoms on a given day, and explanatory fixed effects variables were: day since symptom onset, age, and sex. Time since symptom onset was also specified as a random slope, and Sample ID as a random intercept. A significant effect of age (p = 0.0165) was demonstrated for RS. Predicted symptom values from the model are plotted against index case age with 95% confidence interval bands. **c)** Longitudinal mucosal antibody measurements were added as fixed effect variables in a univariate fashion to the MEM from b). The predicted change in symptoms per unit increase of antibody signal is presented with 95% confidence intervals, and p-values for the association are plotted on the right (\* p < 0.05; \*\* p<0.01; \*\*\* p<0.001).





**Figure 5 Identification of household contact cases and assessment of their mucosal SARS-CoV-2 antibody responses. a)** Contact cases were classified into case or non-case first by their PCR result on enrolment, followed by seroconversion for either IgM, IgG or IgA against the S-protein, and mucosal antibody levels for either IgM, IgG or IgA against the S-protein at the end of the follow-up. The PCR positive threshold was set at a Ct value <36. The seroconversion threshold was based on the mean + 2\*SD of the log2-transformed pre-SARS-CoV-2 control samples. To identify cases based on mucosal antibodies against S, we used a naive Bayes model that was trained by the mucosal antibody measurements of the positive study participants (cases) and the pre-SARS-CoV-2 control samples (controls). b) Contacts were classified by their household as either the primary (N=9) or a non-primary (N=58) case, based on time of symptom onset. Mucosal antibody responses of the primary household contact cases collected at d0 were correlated with viral load. Spearman correlations were calculated, \* p <0.05, \*\* p<0.01, \*\*\* p<0.001. p-values of borderline significant tests are reported directly in the figure. c) IgM, IgG and IgA antibody responses against Spike protein (S), receptor binding domain (RBD) and nucleocapsid (N), measured in mucosal lining fluid. Data are plotted relative to the time of symptom onset of the index case in the respective household, and pre-SARS-CoV-2 control samples are presented for comparison. A non-parametric loess curve is shown as a red (primary cases) and a blue (non-primary cases) line to visualize the trend over time.





**Figure 6. SARS-CoV-2 infection, viral load and number of symptoms of contact cases, split into four age groups. a)** Proportion of infected household contacts per age group. Sixteen out of 33 primary school-age children (1-12y) were infected (48%), 13 out of 23 children aged 13-18y (56%), 27 out of 50 adults aged 19-49 years (54%) and 19 out of 31 contacts older than 50 years (61%). b) Proportion of asymptomatic disease among household cases (N=75) at study enrolment within each age category. Seven of the children below 12 years were asymptomatic (44%), two of the children up to 18 years (15%), seven of the adults up to 49 years (28%) and two of the contacts older than 50 years (11%). c) The correlation between the total number of reported symptoms and the age of the infected household contacts. Pearson's correlation and significance is depicted in the figure. The shape of the datapoints represents the method by which a contact was classified as a case and the color of the datapoints shows the viral load at study start.